Windtree Therapeutics Inc (WINT) concluded trading on Wednesday at a closing price of $0.27, with 15.97 million shares of worth about $4.31 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -92.92% during that period and on January 08, 2025 the price saw a loss of about -11.02%. Currently the company’s common shares owned by public are about 8.99M shares, out of which, 8.94M shares are available for trading.
Stock saw a price change of -23.02% in past 5 days and over the past one month there was a price change of -27.32%. Year-to-date (YTD), WINT shares are showing a performance of -23.02% which decreased to -97.70% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.29 but also hit the highest price of $14.75 during that period. The average intraday trading volume for Windtree Therapeutics Inc shares is 2.06 million. The stock is currently trading -19.40% below its 20-day simple moving average (SMA20), while that difference is down -43.45% for SMA50 and it goes to -92.83% lower than SMA200.
Windtree Therapeutics Inc (NASDAQ: WINT) currently have 8.99M outstanding shares and institutions hold larger chunk of about 1.81% of that.
The stock has a current market capitalization of $2.42M and its 3Y-monthly beta is at 0.58. It has posted earnings per share of -$18.63 in the same period. It has Quick Ratio of 0.27 while making debt-to-equity ratio of 1.68. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for WINT, volatility over the week remained 14.94% while standing at 11.17% over the month.
Stock’s fiscal year EPS is expected to rise by 94.00% while it is estimated to increase by 49.47% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Ladenburg Thalmann on June 26, 2020 offering a Buy rating for the stock and assigned a target price of $12.25 to it.
